蒽环类药物治疗非霍奇金淋巴瘤的药物经济学研究

Pharmacoeconomic study of anthracycline in the treatment of non-Hodgkin’s lymphoma

目的评价3种化疗方案治疗非霍奇金淋巴瘤(NHL)的成本-效果。方法研究纳入100例NHL患者,均采取CHOP方案(环磷酰胺、蒽环类药物、长春新碱和泼尼松)治疗,按蒽环类药物选择不同分为表柔比星组38例、多柔比星脂质体组23例和吡柔比星组39例,采用药物经济学的成本-效果法对3组化疗方案进行回顾性比较分析。结果各组成本分别为:表柔比星组2563.72元、多柔比星脂质体组13 913.77元、吡柔比星组2841.95元;总有效率分别为:表柔比星组84.21%、多柔比星脂质体组86.96%、吡柔比星组79.49%;成本-效果比分别为:30.44、160.00和35.75。不良反应方面,多柔比星脂质体组发生率最低,表柔比星组和吡柔比星组相似。结论成本-效果比分析表柔比星组治疗NHL最优。

Objective To evaluate the cost-effectiveness of three chemotherapy regimens in the treatment of non-hodgkin’s lymphoma(NHL). Methods All of the 100 enrolled NHL patients were taken the CHOP treatment(cyclophosphamide,anthracycline-based drugs,vincristine,and prednisone),and divided into epirubicin group of 38 cases,doxorubicin liposome group of 23 cases,and pirarubicin group 39 cases according to the different anthracycline-based drugs selection. Three groups of chemotherapy regimens were retrospectively analyzed by cost-effectiveness method of pharmacoeconomics. Results The cost of each group was 2563. 72 yuan in epirubicin group,13 913. 77 yuan in doxorubicin liposome group,and 2841. 95 yuan in pirarubicin group,respectively. The total effective rate was 84. 21% in epirubicin group,86. 96% in doxorubicin liposome group,and 79. 49% in pirarubicin group,respectively. The cost-effectiveness ratio was 30. 44,160. 00 and 35. 75,respectively. In terms of adverse reactions,doxorubicin liposome group had the lowest incidence,and the epirubicin group was similar to pirarubicin group. Conclusion The cost-effectiveness analysis showed that the epirubicin group was the best.